Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Assets (2017 - 2025)

Eton Pharmaceuticals' Assets history spans 8 years, with the latest figure at $92.1 million for Q4 2025.

  • On a quarterly basis, Assets rose 21.01% to $92.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $92.1 million, a 21.01% increase, with the full-year FY2025 number at $92.1 million, up 21.01% from a year prior.
  • Assets hit $92.1 million in Q4 2025 for Eton Pharmaceuticals, down from $104.5 million in the prior quarter.
  • Over the last five years, Assets for ETON hit a ceiling of $104.5 million in Q3 2025 and a floor of $21.5 million in Q3 2022.
  • Historically, Assets has averaged $44.1 million across 5 years, with a median of $31.1 million in 2021.
  • Biggest five-year swings in Assets: decreased 25.62% in 2022 and later soared 219.5% in 2025.
  • Tracing ETON's Assets over 5 years: stood at $27.5 million in 2021, then decreased by 8.87% to $25.0 million in 2022, then rose by 26.81% to $31.7 million in 2023, then soared by 139.83% to $76.1 million in 2024, then rose by 21.01% to $92.1 million in 2025.
  • Business Quant data shows Assets for ETON at $92.1 million in Q4 2025, $104.5 million in Q3 2025, and $101.7 million in Q2 2025.